Cytek Biosciences (NASDAQ:CTKB – Get Free Report) announced its earnings results on Wednesday. Cytek Biosciences had a negative net margin of 36.25% and a negative return on equity of 10.07%. Recurring revenue continued to strengthen, with service revenue up 10% to $15.6 million and combined reagents and service revenue representing 35% of trailing-12-month revenue. Cytek Biosciences Stock PerformanceCytek Biosciences stock traded down $0.10 during midday trading on Wednesday, reaching $4.18. See AlsoReceive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.